We identify the “Wants” of Roche Diagnostics in regular reviews with our Business and R&D functions. The “Wants” cover short-term as well as mid- and long-term goals. We work closely with the potential partner to answer questions that focus on unmet medical needs, integration into existing platforms and assay menus, reimbursement, connectivity with our platforms, data sourcing, decision support and future trends with disruptive potential.

In order to be able to answer those questions during evaluation, we need to rely on data provided by the partner for each potential opportunity.

Once a new opportunity is identified, dedicated negotiation teams will work alongside our partners to complete the deal. We do not have any preconceived notions on the type of deals we should make. Our business development organisation can manage each transaction type and can easily change the structure to suit the needs of each of the opportunities and partners. We are flexible and consider a variety of deal types that range from licensing and acquisitions, to option deals and collaboration/partnering agreements, depending on what is best for all parties. If the opportunity permits, we work collaboratively with Pharma Partnering and Genentech Partnering to ensure the best outcome for the patients and the partners. Following execution of co-development projects we will have alliance management teams which work closely with the partner to set the development up for success.